107 related articles for article (PubMed ID: 34190333)
21. A novel LEMD3 mutation common to patients with osteopoikilosis with and without melorheostosis.
Couto AR; Bruges-Armas J; Peach CA; Chapman K; Brown MA; Wordsworth BP; Zhang Y
Calcif Tissue Int; 2007 Aug; 81(2):81-4. PubMed ID: 17622481
[TBL] [Abstract][Full Text] [Related]
22. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
[TBL] [Abstract][Full Text] [Related]
23. Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case Series.
Gnoli M; Staals EL; Campanacci L; Bedeschi MF; Faletra F; Gallone S; Gaudio A; Mattina T; Gurrieri F; Percesepe A; Neri I; Virdi A; Tremosini M; Milanesi A; Brizola E; Pedrini E; Sangiorgi L
Calcif Tissue Int; 2019 Aug; 105(2):215-221. PubMed ID: 31129707
[TBL] [Abstract][Full Text] [Related]
24. Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
Allegrezza MJ; Rutkowski MR; Stephen TL; Svoronos N; Perales-Puchalt A; Nguyen JM; Payne KK; Singhal S; Eruslanov EB; Tchou J; Conejo-Garcia JR
Cancer Res; 2016 Nov; 76(21):6253-6265. PubMed ID: 27803104
[TBL] [Abstract][Full Text] [Related]
25. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
26. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
27. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
28. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in
Weisner J; Landel I; Reintjes C; Uhlenbrock N; Trajkovic-Arsic M; Dienstbier N; Hardick J; Ladigan S; Lindemann M; Smith S; Quambusch L; Scheinpflug R; Depta L; Gontla R; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Maghnouj A; Müller MP; Pohl M; Teschendorf C; Wolters H; Viebahn R; Tannapfel A; Uhl W; Hengstler JG; Hahn SA; Siveke JT; Rauh D
Cancer Res; 2019 May; 79(9):2367-2378. PubMed ID: 30858154
[TBL] [Abstract][Full Text] [Related]
30. Buschke-Ollendorff syndrome: absence of LEMD3 mutation in an affected family.
Yadegari M; Whyte MP; Mumm S; Phelps RG; Shanske A; Totty WG; Cohen SR
Arch Dermatol; 2010 Jan; 146(1):63-8. PubMed ID: 20083694
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
[No Abstract] [Full Text] [Related]
32. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
33. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
[TBL] [Abstract][Full Text] [Related]
34. Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
Baretti M; Personeni N; Destro A; Santoro A; Rimassa L
Cancer Biol Ther; 2018 Aug; 19(8):659-663. PubMed ID: 29580164
[TBL] [Abstract][Full Text] [Related]
35. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
37. Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy.
Edwards EA; Phelps AS; Cooke D; Frieden IJ; Zapala MA; Fullerton HJ; Shimano KA
Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32859736
[TBL] [Abstract][Full Text] [Related]
38. Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.
Dagogo-Jack I
J Thorac Oncol; 2020 Oct; 15(10):e174-e176. PubMed ID: 32981611
[No Abstract] [Full Text] [Related]
39. Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.
De Dosso S; Nucifora M; Sahnane N; Epistolio S; Riveiro ME; Bertolini V; Bucci E; Boldorini R; Freguia S; Frattini M; Saletti P
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2994-3003. PubMed ID: 32271417
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
